glp-1 drugs covered by insurance Employers Take a Variety of Approaches to Coverage How Employers Can Manage GLP-1

Copyright 2023 JPMorgan Chase & Co

[DOI] [PMC free article] [PubMed] [Google Scholar] 19.Kittner S.L., Talbott A.L., Vishneski S.R., Narbaiza J., Shields J.S

Serious events (like severe pancreatitis or major liver issues) have been rare and similar to placebo so far, but long-term safety is still being monitored in ongoing phase 3 programmes

This distinction is important because it may represent a decrease in craving itself

Additional analyses were conducted with a modified intention-to-treat definition for drug use so that patients were censored from follow-up on the date of switch to, or add on of, the other study drug (ie, follow-up among patients treated with DPP4 inhibitors was censored on the date of a GLP1 receptor agonist prescription, and vice versa)